Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
2022 · The Journal of Clinical Endocrinology & Metabolism · 60 citations
https://doi.org/10.1210/clinem/dgac513
M
Michael Højby Rasmussen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
131
Papers
3.2K
Citations
35
h-index
59
i10-index
Michael Højby Rasmussen is an academic researcher from Novo Nordisk (Denmark). The author has contributed to research in topics: Growth Hormone and Insulin-like Growth Factors & Childhood Cancer Survivors' Quality of Life & Diet and metabolism studies. The author has an h-index of 35, co-authored 112 publications.
ORCID: 0000-0002-2210-0366Papers by this author
worksUnderstanding burden of illness for child growth hormone deficiency
2017 · Quality of Life Research · 48 citations
https://doi.org/10.1007/s11136-017-1529-1
Understanding Treatment Burden for Children Treated for Growth Hormone Deficiency
2017 · Patient · 48 citations
https://doi.org/10.1007/s40271-017-0237-9
Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
2018 · PharmacoEconomics - Open · 9 citations
https://doi.org/10.1007/s41669-018-0082-3
Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
2021 · Clinical Pharmacokinetics · 8 citations
https://doi.org/10.1007/s40262-021-00990-7
The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn’s disease
2025 · Scandinavian Journal of Gastroenterology · 2 citations
https://doi.org/10.1080/00365521.2025.2459236
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat